NASDAQ
Avalo Therapeutics, Inc. (AVTX) has a free cash flow growth of -24.18% as of Friday, May 29, 2026. This represents a 589.32% decrease compared to its 12-month average of -3.51%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.